JENKEM(SH:688356)2023-08-28 16:00Financial Performance - The company reported a revenue of 100 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year[14]. - The company's operating revenue for the first half of the year was CNY 214,768,978.37, a decrease of 20.18% compared to the same period last year[20]. - In the first half of 2023, the company's revenue was CNY 171.43 million, a decrease of 20.18% compared to the same period in 2022[56]. - The net profit attributable to shareholders decreased by 38.73% to CNY 68,260,481.92, primarily due to reduced operating revenue and increased costs[22]. - Basic earnings per share fell by 39.25% to CNY 1.13, while diluted earnings per share decreased by 39.13% to CNY 1.12[21]. - The comprehensive gross margin was 78.22%, a decrease of 6.98 percentage points from the previous year[57]. - The company reported a net cash flow from operating activities of CNY 111,261,003.75, down 26.38% from the previous year[20]. - The company's total assets increased by 1.78% to CNY 1,325,787,407.16 compared to the end of the previous year[21]. - The total liabilities increased to CNY 80,076,712.14 from CNY 77,801,659.23, marking an increase of approximately 2.9%[165]. Research and Development - The R&D investment for new products and technologies increased by 30%, totaling 15 million RMB in the first half of 2023[14]. - Research and development expenses accounted for 16.44% of operating revenue, down from 19.99% in the same period last year, a decrease of 3.55 percentage points[21]. - The company has developed over 600 types of PEG products and provides customized development and industrial production based on client needs[28]. - The company has filed 14 new invention patents during the reporting period, with a total of 78 applications and 102 granted patents cumulatively[44]. - The company is actively developing a series of PEG-modified drugs and third-class medical devices, with several products in the pipeline for cancer treatment and other applications[42]. - The company has established long-term strategic partnerships in the fine chemical field of PEG and its derivatives, becoming a leading player in the domestic market[37]. - The company has accumulated significant technical expertise in PEG modification technologies, covering first, second, and third-generation PEG derivatives[39]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[14]. - A strategic acquisition of a local competitor is in progress, expected to enhance the company's product offerings and market reach[14]. - The company is focusing on the development of LNPs delivery technology, which is increasingly being applied in innovative drugs globally[40]. - The company aims to enhance customer cooperation through innovative technology services and customized PEG derivatives[36]. - The company is preparing for future growth by strengthening its sales team and market expansion efforts while advancing key R&D projects[59]. Environmental Compliance and Sustainability - The management emphasized the importance of sustainable practices in future operations, aligning with global environmental standards[14]. - The company has implemented a comprehensive pollution prevention strategy, ensuring that all major pollutants are effectively treated and comply with national standards[1]. - The company has invested in the maintenance and upgrade of environmental protection facilities, including the wastewater treatment station and air pollution control systems[108]. - The company received the title of "Green Factory" at the provincial level from the Tianjin Municipal Bureau of Industry and Information Technology on June 28, 2023[113]. - The company is committed to environmental compliance and has been exempted from forced production cuts due to heavy pollution weather[65]. Shareholder and Governance Matters - The company is committed to adhering to various regulations regarding stock transfer and shareholder commitments, ensuring compliance with the Shanghai Stock Exchange rules[119]. - The company reported a 12-month lock-up period for shares held by directors and senior management after the IPO, with a potential extension of 6 months if the stock price falls below the IPO price during the first 6 months post-IPO[120]. - The company will comply with regulations regarding share transfer limitations and will publicly apologize if any commitments regarding share transfers are violated[121]. - The company plans to implement measures to stabilize its stock price if the closing price falls below 120% of the audited net asset value per share for five consecutive trading days[122]. - The company will propose a profit distribution plan or capital reserve transfer to increase share capital within 10 trading days if stabilization measures are triggered[122]. Financial Management and Fund Utilization - The total amount used for share buybacks will not exceed 50% of the net profit attributable to the parent company from the previous fiscal year[123]. - The company has achieved a funding utilization rate of 85.17% for the current year[138]. - The company reported a total of RMB 40,000,000 allocated for research and development projects, with a 100% utilization rate[141]. - The company plans to use up to RMB 180 million of temporarily idle raised funds for cash management, ensuring the safety and liquidity of the investments[143]. - The company has a cash management plan that allows for rolling use of funds within a 12-month period[143].